Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00507884 | Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors | unknown | — | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04669613 | Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell Carcinoma(CUDI-RCC) | unknown | N/A | 10 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04609293 | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma | unknown | — | 30 | Peking University First HospitalOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04244136 | Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries | unknown | — | 32 | Assiut UniversityOTHER | 0 | Oct 8, 2020 | clinicaltrials |
| NCT03086174 | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma | unknown | Phase 1 | 24 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04424472 | Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma | unknown | N/A | 50 | University of Kansas Medical CenterOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03226886 | TRACERx Renal CAPTURE Sub-study(TRACERxRenal) | unknown | — | 360 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04392076 | Image Guided RFA/MWA/CRYO of RCC Biomarker Profile Study | unknown | — | 43 | University of LeedsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT04385654 | Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 40 | West China HospitalOTHER | 0 | May 13, 2020 | clinicaltrials |
| NCT04146831 | Sintilimab in FH-deficient Renal Cell Carcinoma | unknown | Phase 2 | 37 | West China HospitalOTHER | 0 | May 12, 2020 | clinicaltrials |
| NCT03259477 | RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC | unknown | N/A | 100 | Xuanwu Hospital, BeijingOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04268368 | Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors(ICI-DISCOVER) | unknown | — | 200 | Università Politecnica delle MarcheOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03522155 | Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies | unknown | N/A | 136 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT02928692 | Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium(MAPOCD) | unknown | Phase 3 | 750 | RenJi HospitalOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03571438 | Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors(COMBOREIN) | unknown | N/A | 100 | University Hospital, GrenobleOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01447199 | The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) | unknown | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT04213664 | Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.(LMR) | unknown | — | 4,666 | Corporacion Parc TauliOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03694912 | Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers | unknown | — | 426 | Yonsei UniversityOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03592199 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib(SuAx) | unknown | Phase 2 | 7 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04060537 | Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer(ARTIST_RCC) | unknown | — | 12 | CCTU- Cancer ThemeOTHER | 0 | Aug 19, 2019 | clinicaltrials |
| NCT04049344 | Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04005820 | Impact of Tumour 1q Gain in French Pediatric and Young Adult Patients With Renal Tumours(UMBRELLA) | unknown | N/A | 510 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT03928964 | MEtatastic Renal Carcinoma LINes(MERLIN) | unknown | — | 440 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03667885 | Non-Invasive Diagnostics of Small Renal Masses(NISar) | unknown | — | 160 | Odense University HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03734614 | Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma | unknown | — | 260 | RenJi HospitalOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT03630692 | Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs(TOPTACOS) | unknown | — | 158 | Institut Cancerologie de l'OuestOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT01465425 | Extracolonic Findings on Computed Tomography (CT) Colonography(ACRIN7151) | unknown | — | 520 | American College of Radiology Imaging NetworkNETWORK | 0 | Oct 11, 2018 | clinicaltrials |
| NCT03692533 | Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma | unknown | N/A | 80 | Assiut UniversityOTHER | 0 | Oct 2, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT03062410 | Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma(QUANARIE) | unknown | N/A | 56 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01809119 | Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy | unknown | N/A | 242 | University of Sao PauloOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT03442647 | Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function | unknown | N/A | 30 | Thomas MuellerOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT03218319 | Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)(VAPANCR) | unknown | N/A | 200 | University Hospital, AngersOTHER_GOV | 0 | Jul 14, 2017 | clinicaltrials |
| NCT03033186 | Everolimus TDM to Predict Long Term Toxicity(Foresight) | unknown | — | 40 | Maastricht University Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT03149523 | Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors(ExhauCRF) | unknown | — | 150 | European Georges Pompidou HospitalOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT02330783 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | unknown | Phase 2 | 106 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT03129724 | Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 0 | Apr 26, 2017 | clinicaltrials |
| NCT00184015 | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | unknown | Phase 1 / Phase 2 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT03094949 | Comparison Between Partial Nephrectomy and Ablation for Renal Tumor | unknown | N/A | 200 | Chinese PLA General HospitalOTHER | 1 | Mar 29, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Dec 31, 2020source: clinicaltrials